



Biom'up continues its ascent with the promising research and development project progression: HEMOBLAST™ Bellows.

Lyon (France), April 1, 2015

Biom'Up announced today that it has received FDA IDE approval to begin studies in human patients on the HEMOBLAST™ Bellows hemostatic powder and delivery system. The initial phase of study will focus on Biom'Up's system for evaluating bleeding severity as well as product safety followed by a multi-center, multi-national pivotal trial.

About Biom'Up

Founded in 2005, Biom'Up develops medical devices composed of patent-protected biopolymers. With broad expertise in biomaterials, we create innovative and clinically proven products that are used in many surgical specialties - orthopedics, spine, cardiothoracic, general, maxillofacial and dental. We are committed to the design, development and delivery of novel, high-performing solutions that make life easier for surgeons and better for patients.

About Biom'up:

CEO: Etienne BINANT

Founder, Deputy CEO and Chief Scientific Officer: Patricia FOREST

Chief Medical Officer: William D. SPOTNITZ M.D, M.B.A

Contact: Rick DiBlasi, *Executive VP US Commercial Operations*

r.diblas@biomup.com

www.biomup.com